Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net income including noncontrolling interests	$ 57,383	$ 111,293
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	25,826	25,875
Share-based compensation expenses related to equity classified awards	6,075	5,645
Amortization and write-off of program rights	202,552	187,073
Amortization of deferred carriage fees	4,920	5,100
Unrealized foreign currency transaction loss	2,504	1,626
Amortization of deferred financing costs and discounts on indebtedness	1,750	1,938
Deferred income taxes	(4,011)	(6,269)
Other, net	(2,230)	103
Changes in assets and liabilities:
Accounts receivable, trade (including amounts due from related parties, net)	30,704	15,893
Prepaid expenses and other assets	63,606	76,032
Program rights and obligations, net	(193,006)	(370,304)
Deferred revenue	(4,575)	(64,702)
Accounts payable, accrued liabilities and other liabilities	(40,629)	(121,822)
Net cash provided by (used in) operating activities	150,869	(132,519)
Cash flows from investing activities:
Capital expenditures	(6,720)	(11,498)
Proceeds from sale of investments	0	4,493
Other investing activities, net	3,936	0
Net cash used in investing activities	(2,784)	(7,005)
Cash flows from financing activities:
Principal payments on long-term debt	(16,875)	(8,438)
Deemed repurchases of restricted stock units	(3,961)	(6,012)
Principal payments on finance lease obligations	(1,129)	(1,015)
Distributions to noncontrolling interests	(1,168)	(11,502)
Purchase of noncontrolling interests	0	(1,343)
Net cash used in financing activities	(23,133)	(28,310)
Net increase (decrease) in cash and cash equivalents from operations	124,952	(167,834)
Effect of exchange rate changes on cash and cash equivalents	(5,006)	1,764
Cash and cash equivalents at beginning of period	570,576	930,002
Cash and cash equivalents at end of period	$ 690,522	$ 763,932